Q4 2024 EPS Estimates for Charles River Laboratories International, Inc. Boosted by Analyst (NYSE:CRL)

Posted by Defense World Staff on Sep 8th, 2023

Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) – Zacks Research lifted their Q4 2024 EPS estimates for shares of Charles River Laboratories International in a report released on Monday, September 4th. Zacks Research analyst M. Mondal now forecasts that the medical research company will earn $2.82 per share for the quarter, up from their previous forecast of $2.79. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.48 per share.

Other equities analysts have also recently issued research reports about the company. Bank of America boosted their price objective on Charles River Laboratories International from $235.00 to $245.00 and gave the company a “buy” rating in a report on Thursday, August 10th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Charles River Laboratories International from $260.00 to $250.00 in a research report on Friday, May 12th. Wells Fargo & Company cut their price target on shares of Charles River Laboratories International from $290.00 to $280.00 in a report on Friday, May 12th. TheStreet cut Charles River Laboratories International from a “b-” rating to a “c” rating in a research report on Thursday, May 11th. Finally, Credit Suisse Group dropped their target price on Charles River Laboratories International from $260.00 to $255.00 in a research note on Friday, May 12th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.80.

Check Out Our Latest Stock Analysis on Charles River Laboratories International

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $204.42 on Thursday. The firm has a fifty day simple moving average of $206.84 and a two-hundred day simple moving average of $204.05. Charles River Laboratories International has a 52 week low of $181.22 and a 52 week high of $262.00. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $10.48 billion, a P/E ratio of 21.68, a PEG ratio of 1.83 and a beta of 1.33.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $2.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.06. Charles River Laboratories International had a return on equity of 18.99% and a net margin of 11.58%. The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the firm earned $2.77 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 700 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $216.52, for a total transaction of $151,564.00. Following the completion of the sale, the executive vice president now owns 24,983 shares of the company’s stock, valued at $5,409,319.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 24th. The shares were purchased at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $198,790. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 700 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $216.52, for a total transaction of $151,564.00. Following the completion of the sale, the executive vice president now directly owns 24,983 shares of the company’s stock, valued at approximately $5,409,319.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,934 shares of company stock valued at $1,722,048. Company insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Venturi Wealth Management LLC acquired a new position in Charles River Laboratories International in the 1st quarter valued at about $25,000. Lindbrook Capital LLC lifted its holdings in Charles River Laboratories International by 97.0% during the 2nd quarter. Lindbrook Capital LLC now owns 132 shares of the medical research company’s stock worth $28,000 after buying an additional 65 shares during the last quarter. Desjardins Global Asset Management Inc. acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at $30,000. Tsfg LLC grew its stake in Charles River Laboratories International by 49.1% during the 2nd quarter. Tsfg LLC now owns 158 shares of the medical research company’s stock worth $33,000 after buying an additional 52 shares during the last quarter. Finally, HighMark Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at $45,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).